High-Risk Drug Class Audit
NEW August 2023
Section N of the MDS 3.0 v1.18.11 has been significantly changed!
Beginning October 1, 2023, Long-Term Care providers will encode High-Risk Drugs by class – any drugs in those specific classes that were administered to the resident during the 7-day look-back period.
These MDS items require that there is documentation of the indication for each of those high-risk drugs within the resident’s medical record. The physician’s/physician extender’s order must provide that indication. F641 requires that the assessment must accurately reflect the resident’s status.
To prepare for assessment and encoding of Section N, Briggs High-Risk Drug Class Audit is used with each resident that receives any one or more of the drug classes identified as taken during the 7-day look-back period. Included in the audit are these prompts:
Identification of the high-risk drug class
Name of the drug
Physician diagnosis or indication for the drug administered
Dosage and frequency
Date drug initiated
Identification of the prescribing physician/physician extender
Location of diagnosis/indication for the use of the drug present within the resident's medical record
Orders for labs pertinent to the administration of the drug as well as monitoring for adverse reactions on the resident-specific care plan
Space for additional notes and comments pertinent to the audit
Size: 11" x 8 ½"
Print: Black ink, 2-sides different
Punching: 5-holes top and side
Packaging: 100 per pad